Cambridge Healthtech Institute’s 5th Annual
Agonist Immunotherapy Targets
Stepping on the Gas with Costimulatory Agents
April 11-12, 2019
The immunotherapies industry is currently dominated by antagonist antibodies such as PD-1 and CTLA-4. However, it is clear that antagonists alone are not enough to elicit response in the majority of patients, hence a rising interest in agonists targets.
CHI’s Agonist Immunotherapy Targets conference will examine these modalities and their treating disease. Agonists showing the most promise, including OX40, CD27, GITR, and 4-1BB, will be covered in clinical case studies by examining the data as well as the biology and mechanisms. Emerging agonists, including TNFR receptors, ICOS, STING, and VISTA will also be discussed. Focus will be given throughout to potential combination immunotherapies to ensure durable antitumor response. Overall, this event will emphasize strategies for target discovery to ensure continued growth and success for immunotherapies.
CLINICAL DEVELOPMENTS, INCLUDING OX40, CD27, GTIR
OX40: Is Timing Everything?
Brendan Curti, MD, Director of the Melanoma Program, Cytokine and Adoptive Immunotherapy and Genitourinary Oncology Research, Providence Portland Medical Center
William L. Redmond, PhD, Associate Member, Laboratory of Cancer Immunotherapy, Director, Immune Monitoring Laboratory, Providence Portland Medical Center
Agonist Bispecific Antibodies Delivering the Next Immuno-Oncology Breakthrough
Mihriban Tuna, PhD., Vice President, Drug Discovery, F-star Biotechnology Ltd.
ATOR-1017, A 4-1BB Antibody Developed for Tumor Directed Immunotherapy of Cancer
Peter Ellmark, PhD, Vice President, Discovery, Alligator Bioscience
PD1-Fc-OX40L for Cancer Immunotherapy
Taylor Schreiber, PhD., Chief Scientific Officer, Research & Development, Shattuck Labs, Inc.
EMERGING AGONIST THERAPEUTICS
The Appeal of The TNFR2 Target for Immunotherapy: Tregs and Tumor Oncogenes
Denise L Faustman, M.D., PhD., Director of Immunobiology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School
Development of TNF Superfamily Agonists: 4-1BB Ligand Fusion Shows Anti-Tumor Activity In Vivo
Andreas Raue, PhD., Associate Director, Research, Merrimack Pharmaceuticals
A Novel Systemically Delivered STING Pathway Agonist Therapy Demonstrates Robust Anti-Tumor Efficacy in Multiple Murine Cancer Models
Christopher Thanos, PhD., CEO, Actym Therapeutics
* The program is subject to change without notice, due to unforeseen reason.